摘要
目的:对四妙丸超微制剂与传统制剂治疗佐剂性关节炎(AA)大鼠的药效与免疫调节作用进行比较研究,为类风湿关节炎(RA)临床合理用药提供试验依据。方法:以AA大鼠为实验动物,分别设置四妙丸超微制剂高剂量组(0.71g/kg)、超微制剂低剂量组(0.18g/kg)、传统制剂(粗粉)高剂量组(2.16g/kg)、传统制剂低剂量组(0.54g/kg),连续灌胃21天,考察四妙丸超微制剂与传统制剂对AA大鼠体重、足趾容积、脏器指数(脾脏、胸腺指数)、血清炎症因子(SOD、MDA、NO)及细胞因子IL-1β、IL-6的影响。结果:四妙丸超微制剂与传统制剂均可显著改善AA大鼠的足肿胀及炎症反应,降低血清中IL-1β、IL-6的含量,但四妙丸超微制剂的最小有效剂量较其传统制剂降低。结论:四妙丸超微制剂在改善足肿胀方面优于其传统制剂。
Objective：Clarify the effect of ultrafine powder of simiaowan on RA rats, and provide experimental basis for clinical medication. Methods：Drugs were administered to AA rats for 21 days respectively with ultrafine powder 0.71g/kg, 0. 18g/kg（low dose group）,traditional preparations（coarse powder）2.16g/kg（high dose group）, 0.54g/kg（low dose group）. The volume of RA rats toes,organ index（ spleen and thymus index）, serum inflammation factors （SOD, MDA, NO, IL-1β, IL-6） were investigated to make clear the pharmacodynamic action and mechanism of ultrafine powder. Results and Conclusion ： Ultrafine powder and coarse powder of simiaowan all could inhibit AA rats foot swelling obviously, rise SOD activity, reduced the MDA, NO, IL-1β, IL-6 content in serum, and the effect of ultrafine powder was better than coarse powder when the dose was equal.
出处
《亚太传统医药》
2016年第15期15-18,共4页
Asia-Pacific Traditional Medicine
基金
湖南省战略性新兴产业产学研结合创新平台项目(2012GK4103)
湖南省高校创新平台项目(13K074)
湖南中医药大学博士自然科学基金(9982-1001-015)
中药粉体与创新药物省部共建国家重点实验室培育基地开放基金重点项目(2015)
关键词
四妙丸
超微制剂
AA
免疫调节
Simiaowan
Ultrafine Powder
RA
Immune Regulation
